Zyprexa documents ppt 6.

This powerpoint has a selection of pages from documents to do with managing Adverse Drug Event issues.

ZY100737693 Letter re “10%” metabolic ADEs Sep2002

ZY100413599, ZY100413600, ZY100413601 tables Jan 2003 on spont ADEs re diabetes, pancreatitis to June 2002

ZY200399435 email re Prof Newcomer and Csernansky prestn in UK re diabetes and atyps Aug 2002 “they request the literature I reference”

ZY200399435 email re Prof Newcomer and Csernansky prestn in UK re diabetes and atyps Aug 2002

ZY200399435 email re Prof Newcomer and Csernansky prestn in UK re diabetes and atyps Aug 2002 “if I were with Janssen, I’d be throwing some cash at this chap”

ZY201300048 email re pharmacoepidemiol study showing Olz and Clozapine had greater odds ratio for being on antidiabetes meds Oct2002

ZY100570361 copy of letter of a medical director re Zyp weight gain faxed to E-L Mar 2003

ZY200570518 “Tough questions” debated at Lilly Apr2003 mtg

ZY100014182 APA 2003 review dealing with metabolic ADEs

ZY100014182 APA 2003 review dealing with atypicals v typicals debate

ZY100386523 regulatory activity timeline from 1985 to FDA decision 15 Sep 2003

ZY201588819 internal Lilly lit rv on comparative metab ADEs of atypicals undated but latest ref used 2003.

anonymous Lilly reviewer concludes Risp and Quet are more likely to have metab ADEs than current warnings, but also that Olz sits with Cloz as most likely agents to give metabolic ADEs

ZY201588819 internal Lilly lit rv on comparative metab ADEs of atypicals undated but latest ref used 2003.

anonymous Lilly reviewer concludes Risp and Quet are more likely to have metab ADEs than current warnings, but also that Olz sits with Cloz as most likely agents to give metabolic ADEs

ZY201588969 letter to ADA protesting differential warnings on atypicals Jan 2004

ZY201588416 email re “influence plan” diabetes/wght gain Feb 2004

ZY201239720 Competitive info briefing from interviews with Prof Newcomer & other advisors Feb2004

ZYZY201239720 Competitive info briefing from interviews with Prof Newcomer & other advisors Feb 2004

ZY201239728 Competitive info briefing re APA subcommitte Mar2004 ...APA refused to sign on to ADA work until it saw a draft. APA felt that if the ADA pronouncements were politically explosive, it would upset the APA sponsors...

APA = American Psychiatric Association ADA = American Diabetes Association

ZY201239728 Competitive info briefing re APA subcommitte Mar2004

ZY201862763 email re Stahl, Meyer CME on atypicals and diabetes Olanzapine “big offender” June 2004

ZY201238586 Issue management wght gain/diabetes mid 2003

ZY200583203 Issues management and competitive strategy July2003

ZY200192865 Integrating wght gain into the brand promise

ZY200523684 Weight Task Force Jan 2004

ZY200506745 Managing wght gain diabetes concerns CSF marketing Dec 2003

ZY200662252 powerpt pres on response to ADA consensus statement on atypicals & diabetes early 2004

ZY200521530 notes re handling ADA type events.

Feb 2004

ZY200521530 notes re handling ADA type events.

Feb 2004

ZY200521530 notes re handling ADA type events.

Feb 2004

ZY200521530 notes re handling ADA type events.

Feb 2004

ZY200581528 email: our “position (no differential between atypicals on diabetes) is making us look foolish” Mar 2004

ZY200598805 emails re literature saying antipsychotics of equal efficacy Jan 2004

ZY201607921 marketplace strategy managing wgt gain Jan 2005

Slide 1

Transcript Slide 1

Zyprexa documents ppt 6.

ZY100014182 APA 2003 review dealing with metabolic ADEs

ZY100014182 APA 2003 review dealing with atypicals v typicals debate

Directory